Yang Hua, Liu Yongjun
Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Surg. 2022 Jun 16;9:889294. doi: 10.3389/fsurg.2022.889294. eCollection 2022.
Kinesin family member 2A (KIF2A) is reported as an oncogene and a potential biomarker for progression and prognosis in several cancers such as cervical, ovarian, and gastric. However, its clinical value in basal-like breast cancer (BLBC) is unclear. This study aims to evaluate KIF2A expression and its correlation with clinical features and survival rates in BLBC patients.
KIF2A mRNA and protein expressions in tumor and adjacent tissues from 89 BLBC patients are assessed by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry assays, respectively.
Both KIF2A protein (< 0.001) and mRNA expressions (< 0.001) were higher in tumor than in adjacent tissue. Besides, tumor KIF2A protein expression was positively correlated with N (= 0.028) and TNM (= 0.014) stages; meanwhile, tumor KIF2A mRNA expression was positively correlated with N stage (= 0.046), TNM stage (= 0.006), and tumor size (= 0.043). Additionally, both tumor KIF2A protein (= 0.035) and mRNA (= 0.039) high expressions were correlated with worse disease-free survival (DFS) but not with overall survival (both > 0.05). Moreover, tumor KIF2A protein expression was higher in relapsed patients than in non-relapsed patients within 3 years (= 0.015) and 5 years (= 0.031), whereas no difference was found between the dead and survivors within 3 years (= 0.057) or 5 years (= 0.107). Lastly, after adjustment, tumor KIF2A mRNA high exhibited a trend that correlated with DFS but without statistical significance (= 0.051).
KIF2A correlates with more frequent lymph node metastasis and worse DFS in BLBC patients, shedding light on its potency as a biomarker for BLBC.
驱动蛋白家族成员2A（KIF2A）在宫颈癌、卵巢癌和胃癌等多种癌症中被报道为一种癌基因以及疾病进展和预后的潜在生物标志物。然而，其在基底样乳腺癌（BLBC）中的临床价值尚不清楚。本研究旨在评估KIF2A在BLBC患者中的表达及其与临床特征和生存率的相关性。
分别通过逆转录定量聚合酶链反应和免疫组织化学分析评估89例BLBC患者肿瘤组织和癌旁组织中KIF2A mRNA和蛋白的表达。
肿瘤组织中KIF2A蛋白（<0.001）和mRNA表达（<0.001）均高于癌旁组织。此外，肿瘤KIF2A蛋白表达与N分期（=0.028）和TNM分期（=0.014）呈正相关；同时，肿瘤KIF2A mRNA表达与N分期（=0.046）、TNM分期（=0.006）和肿瘤大小（=0.043）呈正相关。此外，肿瘤KIF2A蛋白（=0.035）和mRNA（=0.039）高表达均与无病生存期（DFS）较差相关，但与总生存期无关（均>0.05）。此外，复发患者肿瘤KIF2A蛋白表达在3年（=0.015）和5年（=0.031）内高于未复发患者，而在3年（=0.057）或5年（=0.107）内死亡患者与存活患者之间未发现差异。最后，调整后，肿瘤KIF2A mRNA高表达呈现出与DFS相关的趋势，但无统计学意义（=0.051）。
KIF2A与BLBC患者更频繁的淋巴结转移和更差的DFS相关，揭示了其作为BLBC生物标志物的潜力。
